EGFR and nasopharyngeal carcinoma: The EGFR-TKI icotinib also has a radiosensitising effect in preclinical studies on cell lines of human nasopharyngeal carcinomas (68) and was well tolerated clinically in a phase I study with concurrent intensity-modulated radiotherapy (76).